EUVIMEDEUVIMED entdecken
Crossref

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

Alexander Ring, Antonia Maria Müller

healthbook TIMES Oncology Hematology · 2019

DOI: 10.36000/hbt.oh.2019.01.005 ↗

Kurz gefasst

Fachartikel in der Zeitschrift healthbook TIMES Oncology Hematology, 2019. Verfasst von Alexander Ring und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Diffuse large B-cell lymphoma (DLBCL) is the most common neoplasm of the lymphatic system. Treatment and clinical management are difficult in the relapsed/refractory (R/R) setting. Chimeric antigen receptor (CAR) T cells are genetically engineered using autologous patient lymphocytes and have shown very promising results in the treatment of relapsed and refractory cases of DLBCL.

Methods

A 64-year-old male patient with refractory DLBCL and central nervous system (CNS) involvement after 9 lines of therapy was treated with CD19-specific CAR T cell therapy at the Department of medical oncology and hematology at the University Hospital of Zurich and followed-up for 10 weeks.

Results

Autologous lymphocytes were successfully harvested and transfected/expanded for CAR T cell production. Conditioning chemotherapy and CAR T infusion was well tolerated. Post-infusion side effects were mild (cytokine release syndrome [CRS] grade 1−2), with limited signs of neurotoxicity. Ten weeks after CAR T cell therapy, an excellent response could be documented via PET-CT. The CNS lesion disappeared as assessed via cranial MRI.

Conclusion

CD19-targeted CAR T cell therapy is a revolutionary treatment option for heavily pre-treated R/R DLBCL even in the setting of CNS involvement.

Zitieren

APA

Ring, A., & Müller, A. M. (2019). CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement. healthbook TIMES Oncology Hematology. https://doi.org/10.36000/hbt.oh.2019.01.005

Vancouver

Ring A, Müller AM. CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement. healthbook TIMES Oncology Hematology. 2019. doi:10.36000/hbt.oh.2019.01.005

BibTeX
@article{Ring2019,
  author = {Ring, Alexander and Müller, Antonia Maria},
  title = {CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement},
  journal = {healthbook TIMES Oncology Hematology},
  year = {2019},
  doi = {10.36000/hbt.oh.2019.01.005}
}
Kostenlos starten →